Join us for a welcome address from Governor Matt Meyer.

Delaware’s longstanding leadership in industrial production has positioned the state to lead the next revolution in advanced manufacturing: making cutting-edge biopharmaceutical products at scale. In this session, global industry, investment and scientific leaders will explore the technological breakthroughs, workforce development imperatives and national security stakes at play in this unfolding new “space race” for our state and nation.

Artificial intelligence (AI) is dramatically reshaping the discovery and development of new medical technologies and therapies – ushering in a future of predictive, personalized, and preventative medicine. Across Delaware’s life science ecosystem, AI is accelerating drug discovery, enhancing diagnostic accuracy and improving patient care. We’ll hear how researchers are deploying this powerful technology and the technical and ethical challenges involved in navigating this immensely complex and exciting terrain.

Synthetic biology and advanced biomaterials are enabling new capabilities across health, sustainability, and industrial applications—but translating innovation into impact requires more than strong science. Panelists will discuss how the region's market-leading ecosystem—spanning academia, industry, and government—can engage, collaborate, and contribute to moving synthetic biology innovations from promising molecules to practical solutions

For more than a century, Delaware has been the premier global corporate venue thanks to a business-friendly environment, attractive tax advantages and our renowned Court of Chancery. The country’s top experts on Delaware’s unique legal and business assets will discuss what makes the First State the still-undisputed First Choice for incorporation and investment – including, importantly, for emerging and established life science enterprises.

Delaware’s world class legal community has unrivaled expertise advising life science companies of every size and stage. In this session, legal and business experts will offer practical insights on critical considerations for early and mid-stage life science companies seeking to raise investment funding, secure strategic partnerships and ultimately go public or become acquired. The panel will discuss key decisions regarding IP protection, governance and capitalization that will mitigate risk and enable growth companies to scale with confidence and maximum strategic options.

Top regional institutions will share their cutting-edge research, exciting emerging technologies and unique capabilities and the many ways the Delaware life science ecosystem can leverage these assets to accelerate sector growth. Leaders from Delaware Biotechnology Institute, Delaware Health Information Network, Delaware State University, F3 Tech Biomanufacturing Hub and the Helen F. Graham Cancer Center & Research Institute at ChristianaCare will share their focus and strategies and participate in an interactive roundtable discussion with audience Q&A. Entrepreneurs, investors and companies of all sizes won't want to miss this opportunity to identify specific collaborations that can add value to your bottom line.